
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3910926/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet, The, 2010, 376, 419-430.	13.7	1,182
2	Cerebral Glucose Metabolism in Adults with Hyperactivity of Childhood Onset. New England Journal of Medicine, 1990, 323, 1361-1366.	27.0	881
3	A review of immiscible fluids in the subsurface: Properties, models, characterization and remediation. Journal of Contaminant Hydrology, 1990, 6, 107-163.	3.3	614
4	Decreased β-Amyloid <sub>1-42</sub> and Increased Tau Levels in Cerebrospinal Fluid of Patients With Alzheimer Disease. JAMA - Journal of the American Medical Association, 2003, 289, 2094-103.	7.4	579
5	Epidemiologic Relationships Between A1C and All-Cause Mortality During a Median 3.4-Year Follow-up of Glycemic Treatment in the ACCORD Trial. Diabetes Care, 2010, 33, 983-990.	8.6	389
6	A Transgenic Alzheimer Rat with Plaques, Tau Pathology, Behavioral Impairment, Oligomeric Aβ, and Frank Neuronal Loss. Journal of Neuroscience, 2013, 33, 6245-6256.	3.6	376
7	Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood, 2008, 112, 4284-4291.	1.4	364
8	Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [ <sup>18</sup> F]Cyclofoxy and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 24-42.	4.3	343
9	Caloric restriction increases neurotrophic factor levels and attenuates neurochemical and behavioral deficits in a primate model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 18171-18176.	7.1	334
10	DOPA Decarboxylase Activity in Attention Deficit Hyperactivity Disorder Adults. A [Fluorine-18]Fluorodopa Positron Emission Tomographic Study. Journal of Neuroscience, 1998, 18, 5901-5907.	3.6	314
11	Positron-Emission Tomography and Personality Disorders. Neuropsychopharmacology, 1994, 10, 21-28.	5.4	244
12	Racial and Ethnic Differences in the Relationship between HbA1c and Blood Glucose: Implications for the Diagnosis of Diabetes. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1067-1072.	3.6	221
13	Presynaptic Dopaminergic Deficits in Lesch–Nyhan Disease. New England Journal of Medicine, 1996, 334, 1568-1572.	27.0	195
14	Discordance Between HbA1c and Fructosamine: Evidence for a glycosylation gap and its relation to diabetic nephropathy. Diabetes Care, 2003, 26, 163-167.	8.6	191
15	Positron Emission Tomography in Schizophrenic Patients with and without Neuroleptic Medication. Journal of Cerebral Blood Flow and Metabolism, 1985, 5, 201-206.	4.3	175
16	Cerebrospinal fluid β-amyloid1–42 and tau in control subjects at risk for Alzheimer's disease: The effect of APOE ε4 allele. Biological Psychiatry, 2004, 56, 670-676.	1.3	168
17	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International, 2015, 87, 649-659.	5.2	158
18	Glucose utilization in the temporal cortex of affectively ill patients: Positron emission tomography. Biological Psychiatry, 1987, 22, 545-553.	1.3	149

#	Article	IF	CITATIONS
19	Glycemia Treatment Strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial. American Journal of Cardiology, 2007, 99, S34-S43.	1.6	149
20	Chemogenetic locus coeruleus activation restores reversal learning in a rat model of Alzheimer's disease. Brain, 2017, 140, 3023-3038.	7.6	146
21	Dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sciences, 1987, 40, 2031-2039.	4.3	132
22	The dexamethasone suppression test in patients with primary obsessive-compulsive disorder. Psychiatry Research, 1982, 6, 153-160.	3.3	125
23	Gender-related differences in regional cerebral glucose metabolism in normal volunteers. Psychiatry Research, 1994, 51, 175-183.	3.3	124
24	Evidence for Independent Heritability of the Glycation Gap (Glycosylation Gap) Fraction of HbA1c in Nondiabetic Twins. Diabetes Care, 2006, 29, 1739-1743.	8.6	120
25	Low-level laser therapy for beta amyloid toxicity in rat hippocampus. Neurobiology of Aging, 2017, 49, 165-182.	3.1	111
26	Evidence for Interindividual Heterogeneity in the Glucose Gradient Across the Human Red Blood Cell Membrane and Its Relationship to Hemoglobin Glycation. Diabetes, 2008, 57, 2445-2452.	0.6	109
27	Effects of Acute Stimulant Medication on Cerebral Metabolism in Adults with Hyperactivity. Neuropsychopharmacology, 1993, 8, 377-386.	5.4	106
28	Pharmacologic modelling of Alzheimer's disease. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1986, 10, 599-610.	4.8	101
29	Physostigmine induction of depressive symptomatology in normal human subjects. Psychiatry Research, 1981, 4, 89-94.	3.3	100
30	6-18F-DOPA PET study in patients with schizophrenia. Psychiatry Research - Neuroimaging, 2000, 100, 1-11.	1.8	92
31	Presnyaptic noradrenergic regulation during depression and antidepressant drug treatment. Psychiatry Research, 1980, 3, 93-105.	3.3	91
32	Changes in the properties of normal human red blood cells during in vivo aging. American Journal of Hematology, 2013, 88, 44-51.	4.1	90
33	Naloxone effects on ?-endorphin, cortisol, prolactin, growth hormone, HVA and MHPG in plasma of normal volunteers. Psychopharmacology, 1981, 74, 125-128.	3.1	87
34	Widespread decrease of nicotinic acetylcholine receptors in Parkinson's disease. Annals of Neurology, 2006, 59, 174-177.	5.3	85
35	HbA1c for the Diagnosis of Diabetes and Prediabetes: Is It Time for a Mid-Course Correction?. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5203-5206.	3.6	85
36	Tyramine pressor sensitivity changes during deprenyl treatment. Psychopharmacology, 1985, 86, 432-437.	3.1	83

#	Article	IF	CITATIONS
37	TRH attenuates scopolamine-induced memory impairment in humans. Psychopharmacology, 1990, 100, 84-89.	3.1	79
38	Regional cerebral metabolic asymmetries replicated in an independent group of patients with panic disorder. Biological Psychiatry, 1998, 44, 998-1006.	1.3	78
39	Reproducibility of Resting Cerebral Blood Flow Measurements with H <sub>2</sub> <sup>15</sup> O Positron Emission Tomography in Humans. Journal of Cerebral Blood Flow and Metabolism, 1993, 13, 748-754.	4.3	75
40	Acute effects of high-dose thyrotropin releasing hormone infusions in Alzheimer's disease. Psychopharmacology, 1989, 98, 403-407.	3.1	71
41	Amyloid-β Positron Emission Tomography Imaging Probes: A Critical Review. Journal of Alzheimer's Disease, 2013, 36, 613-631.	2.6	71
42	Incorporating Multidimensional Patient-Reported Outcomes of Symptom Severity, Functioning, and Quality of Life in the Individual Burden of Illness Index for Depression to Measure Treatment Impact and Recovery in MDD. JAMA Psychiatry, 2013, 70, 343.	11.0	70
43	The recovery index: A novel approach to measuring recovery and predicting remission in major depressive disorder. Journal of Affective Disorders, 2017, 208, 369-374.	4.1	67
44	Scopolamine challenges in Alzheimer's disease. Psychopharmacology, 1985, 87, 247-249.	3.1	65
45	In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse, 2003, 48, 39-44.	1.2	64
46	A1C: Does One Size Fit All?. Diabetes Care, 2007, 30, 2756-2758.	8.6	63
47	Episodic secretion of opioid activity in human plasma and monkey CSF: Evidence for a diurnal rhythm. Life Sciences, 1981, 28, 931-935.	4.3	60
48	Physiological effects of high dose naloxone administration to normal adults. Life Sciences, 1982, 30, 2025-2031.	4.3	59
49	Higher in vivo muscarinic-2 receptor distribution volumes in aging subjects with an apolipoprotein E-?4 allele. Synapse, 2003, 49, 150-156.	1.2	59
50	REM sleep suppression induced by selective monoamine oxidase inhibitors. Psychopharmacology, 1982, 78, 137-140.	3.1	58
51	Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2021, 20, 537-547.	10.2	55
52	Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the individual burden of illness index for depression (IBI-D). Journal of Affective Disorders, 2013, 151, 59-65.	4.1	54
53	Biomarkers in the Diagnosis of Alzheimer's Disease: Are We Ready?. Journal of Geriatric Psychiatry and Neurology, 2006, 19, 172-179.	2.3	52
54	Endocrine effects of the cold pressor test: Relationships to subjective pain appraisal and coping. Psychiatry Research, 1984, 12, 227-233.	3.3	50

#	Article	IF	CITATIONS
55	Frequency of HbA1c discordance in estimating blood glucose control. Current Opinion in Clinical Nutrition and Metabolic Care, 2008, 11, 512-517.	2.5	50
56	High-dose naloxone affects task performance in normal subjects. Psychiatry Research, 1983, 8, 127-136.	3.3	49
57	Human plasma melatonin is elevated during treatment with the monoamine oxidase inhibitors clorgyline and tranylcypromine but not deprenyl. Psychiatry Research, 1986, 17, 119-127.	3.3	49
58	Distribution and Kinetics of 3-O-Methyl-6-[18F]fluoro-L-DOPA in the Rhesus Monkey Brain. Journal of Cerebral Blood Flow and Metabolism, 1991, 11, 726-734.	4.3	49
59	Functional magnetic resonance imaging and magnetoencephalography differences associated with APOEε4 in young healthy adults. NeuroReport, 2006, 17, 1585-1590.	1.2	49
60	The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sciences, 1988, 43, 1141-1150.	4.3	48
61	Naloxone Reduces Food Intake in Humans. Psychosomatic Medicine, 1985, 47, 132-138.	2.0	47
62	Longâ€ŧerm imipramine treatment enhances locomotor and food intake suppressant effects of <i>m</i> hlorophenylpiperazine in rats. British Journal of Pharmacology, 1987, 91, 747-752.	5.4	47
63	Opiate receptor avidity and cerebral blood flow in Alzheimer's disease. Journal of the Neurological Sciences, 1997, 148, 171-180.	0.6	47
64	Context-specific memory and apolipoprotein E (ApoE) [varepsilon]4: Cognitive evidence from the NIMH prospective study of risk for Alzheimer's disease. Journal of the International Neuropsychological Society, 2004, 10, 362-70.	1.8	47
65	Biologic Variability in Plasma Glucose, Hemoglobin A1c, and Advanced Glycation End Products Associated with Diabetes Complications. Journal of Diabetes Science and Technology, 2009, 3, 635-643.	2.2	46
66	Patient-reported functioning in major depressive disorder. Therapeutic Advances in Chronic Disease, 2016, 7, 160-169.	2.5	45
67	The Dexamethasone Suppression Test as a Measure of Hypothalamic-Pituitary Feedback Sensitivity and its Relationship to Behavioral Arousal. Neuroendocrinology, 1981, 32, 92-95.	2.5	44
68	Age-Related Changes in Brain Glucose Metabolism in Adults With Attention-Deficit/Hyperactivity Disorder and Control Subjects. Journal of Neuropsychiatry and Clinical Neurosciences, 1998, 10, 168-177.	1.8	44
69	In vitro binding properties and autoradiographic imaging of 3-iodobenzamide ([125I]-IBZM): A potential imaging ligand for D-2 dopamine receptors in spect. Life Sciences, 1988, 42, 2097-2104.	4.3	43
70	Measurement of Posttransfusion Red Cell Survival With the Biotin Label. Transfusion Medicine Reviews, 2014, 28, 114-125.	2.0	43
71	TRH stimulation test in dementia of the Alzheimer type and elderly controls. Psychiatry Research, 1985, 16, 269-275.	3.3	39
72	Abnormalities in the Distributed Network of Sustained Attention Predict Neuroleptic Treatment Response in Schizophrenia. Neuropsychopharmacology, 1998, 19, 36-47.	5.4	38

#	Article	IF	CITATIONS
73	Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia. American Journal of Hematology, 2016, 91, 1195-1201.	4.1	38
74	When the Blood Glucose and the HbA1c Don't Match: Turning Uncertainty Into Opportunity. Diabetes Care, 2012, 35, 2421-2423.	8.6	36
75	Associations of Early Kidney Disease With Brain Magnetic Resonance Imaging and Cognitive Function in African Americans With Type 2 Diabetes Mellitus. American Journal of Kidney Diseases, 2017, 70, 627-637.	1.9	35
76	Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls. Psychopharmacology, 1989, 99, 129-133.	3.1	34
77	Intravenous Dextroamphetamine and Brain Glucose Metabolism. Neuropsychopharmacology, 1997, 17, 391-401.	5.4	33
78	Vitamin D Supplementation in Patients With Type 2 Diabetes: The Vitamin D for Established Type 2 Diabetes (DDM2) Study. Journal of the Endocrine Society, 2018, 2, 310-321.	0.2	33
79	Right frontotemporal activation by tonal memory in dyslexia, an O15 PET study. Biological Psychiatry, 1994, 36, 171-180.	1.3	32
80	Use of an oral stable isotope label to confirm variation in red blood cell mean age that influences HbA1c interpretation. American Journal of Hematology, 2015, 90, 50-55.	4.1	31
81	Sexual Satisfaction and Quality of Life in Major Depressive Disorder Before and After Treatment With Citalopram in the STAR*D Study. Journal of Clinical Psychiatry, 2013, 74, 256-261.	2.2	31
82	Tyramine infusions and selective monoamine oxidase inhibitor treatment. Psychopharmacology, 1981, 74, 8-12.	3.1	30
83	Plasma catecholamines and their metabolites in obsessive-compulsive disorder. Psychiatry Research, 1991, 37, 321-331.	3.3	30
84	Hemoglobin A_1c: Teaching a New Dog Old Tricks. Annals of Internal Medicine, 2010, 152, 815.	3.9	29
85	Failing Compensatory Mechanisms During Working Memory in Older Apolipoprotein E-ε4 Healthy Adults. Brain Imaging and Behavior, 2010, 4, 177-188.	2.1	29
86	Quantitative trait loci affecting the behavior of A/J and CBA/J intercross mice in the elevated plus maze. Mammalian Genome, 2001, 12, 501-507.	2.2	27
87	When HbA1c and Blood Glucose Do Not Match: How Much Is Determined by Race, by Genetics, by Differences in Mean Red Blood Cell Age?. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 707-710.	3.6	27
88	A Double FDG/PET Study of the Effects of Scopolamine in Older Adults. Neuropsychopharmacology, 1994, 10, 191-198.	5.4	26
89	Relationship of Prospective GHb to Glycated Serum Proteins in Incident Diabetic Retinopathy. Diabetes Care, 2008, 31, 151-153.	8.6	26
90	Comparing Multiple Measures of Glycemia: How to Transition from Biomarker to Diagnostic Test?. Clinical Chemistry, 2012, 58, 1615-1617.	3.2	25

#	Article	IF	CITATIONS
91	Hormonal effects of high dose naloxone in humans. Neuropeptides, 1985, 6, 373-380.	2.2	23
92	Metabolic and cognitive changes in hereditary ataxia. Journal of the Neurological Sciences, 1993, 119, 134-140.	0.6	23
93	Abnormalities in sustained attention and anterior cingulate metabolism in subjects with resistance to thyroid hormone. Brain Research, 1996, 723, 23-28.	2.2	23
94	The Brain Metabolic Patterns of Clozapine- and Fluphenazine-Treated Female Patients with Schizophrenia Evidence of a Sex Effect. Neuropsychopharmacology, 1999, 21, 632-640.	5.4	23
95	A method for the continuous calculation of the age of labeled red blood cells. American Journal of Hematology, 2008, 83, 454-457.	4.1	23
96	Effect of vitamin D supplementation on cardiovascular risk in type 2 diabetes. Clinical Nutrition, 2019, 38, 2449-2453.	5.0	23
97	Foot shock induces time and region specific adrenergic receptor changes in rat brain. Pharmacology Biochemistry and Behavior, 1986, 24, 1587-1592.	2.9	21
98	Correlated cholinomimetic-stimulated beta-endorphin and prolactin release in humans. Peptides, 1982, 3, 319-322.	2.4	20
99	Prevalence of microvascular and macrovascular disease in the Glycemia Reduction Approaches in Diabetes - A Comparative Effectiveness (GRADE) Study cohort. Diabetes Research and Clinical Practice, 2020, 165, 108235.	2.8	20
100	Noninvasive Estimation of Normalized Distribution Volume: Application to the Muscarinic-2 Ligand [18F]FP-TZTP. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 420-430.	4.3	19
101	Age and APOE-ε4 genotype influence the effect of physostigmine infusion on the in-vivo distribution volume of the muscarinic-2-receptor dependent tracer [18F]FP-TZTP. Synapse, 2006, 60, 86-92.	1.2	18
102	Are glycated serum proteins ready for prime time?. Lancet Diabetes and Endocrinology,the, 2014, 2, 264-265.	11.4	18
103	Reduced cerebrospinal fluid dynorphin A1–8 in Alzheimer's disease. Biological Psychiatry, 1991, 30, 81-87.	1.3	16
104	Physiologic and neuroendocrine responses to intravenous naloxone in subjects with Alzheimer's disease and age-matched controls. Biological Psychiatry, 1999, 46, 412-419.	1.3	16
105	Is Poor Glycemic Control Associated With Reduced Red Blood Cell Lifespan?. Diabetes Care, 2004, 27, 1013-1014.	8.6	16
106	Stability of CSF β-Amyloid <sub>1–42</sub> and Tau Levels by APOE Genotype in Alzheimer Patients. Dementia and Geriatric Cognitive Disorders, 2006, 22, 48-53.	1.5	16
107	PATIENT-REPORTED OUTCOMES OF QUALITY OF LIFE, FUNCTIONING, AND DEPRESSIVE SYMPTOM SEVERITY IN MAJOR DEPRESSIVE DISORDER COMORBID WITH PANIC DISORDER BEFORE AND AFTER SSRI TREATMENT IN THE STAR*D TRIAL. Depression and Anxiety, 2014, 31, 707-716.	4.1	16
108	Antibodies to biotinylated red blood cells in adults and infants: improved detection, partial characterization, and dependence on red blood cellâ€biotin dose. Transfusion, 2017, 57, 1488-1496.	1.6	16

#	Article	IF	CITATIONS
109	Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. Diabetes Care, 2021, 44, 340-349.	8.6	16
110	Lifetime monoamine oxidase inhibition and sleep. Pharmacology Biochemistry and Behavior, 1982, 16, 429-431.	2.9	15
111	Opiate receptor avidity is reduced in non-motor impaired MPTP-lesioned rhesus monkeys. Brain Research, 1998, 806, 292-296.	2.2	15
112	Chronic clorgyline and pargyline increase apomorphine-induced stereotypy in the rat. Pharmacology Biochemistry and Behavior, 1985, 23, 921-925.	2.9	14
113	Positron emission tomography with 18F-DOPA: Interpretation and biological correlates in nonhuman primates. Psychiatry Research - Neuroimaging, 1992, 45, 153-168.	1.8	14
114	Effects of Previous Major Depressive Illness on Cognition in Alzheimer Disease Patients. American Journal of Geriatric Psychiatry, 2005, 13, 312-318.	1.2	14
115	Opiate receptor avidity in the thalamus is sexually dimorphic in the elderly. Synapse, 2000, 38, 226-229.	1.2	13
116	Hippocampal atrophy in the healthy is initially linear and independent of age. Neurobiology of Aging, 2006, 27, 1385-1394.	3.1	13
117	Hippocampal place cell dysfunction and the effects of muscarinic M <sub>1</sub> receptor agonism in a rat model of Alzheimer's disease. Hippocampus, 2018, 28, 568-585.	1.9	13
118	Regional brain glucose metabolism after acute α2-blockade by idazoxan. Clinical Pharmacology and Therapeutics, 1995, 57, 684-695.	4.7	12
119	Shape of the OGTT glucose response curve: relationship with β-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. BMJ Open Diabetes Research and Care, 2021, 9, e002264.	2.8	12
120	Diurnal Variation in Cerebrospinal Fluid Prolactin Concentration of the Rhesus Monkey. Journal of Clinical Endocrinology and Metabolism, 1981, 52, 857-858.	3.6	11
121	Glutaraldehyde pretreatment blocks phospholipase A2 modulation of adrenergic receptors. Life Sciences, 1985, 36, 25-32.	4.3	11
122	The Ratio of Mesial to Neocortical Temporal Lobe Blood Flow as a Predictor of Dementia. Journal of the American Geriatrics Society, 1997, 45, 329-333.	2.6	11
123	Addisonian crisis in a liver transplant patient due to fluconazole withdrawal. Clinical Transplantation, 1999, 13, 62-64.	1.6	11
124	The Need for Accuracy in Hemoglobin A1c Proficiency Testing: Why the Proposed CLIA Rule of 2019 Is a Step Backward. Journal of Diabetes Science and Technology, 2019, 13, 424-427.	2.2	11
125	Opiate receptor avidity is reduced bilaterally in rhesus monkeys unilaterally lesioned with MPTP. , 1999, 33, 282-288.		10
126	Pseudohypoglycemia: a Cause for Unreliable Finger-Stick Glucose Measurements. Endocrine Practice, 2008. 14. 337-339.	2.1	10

#	Article	IF	CITATIONS
127	Design and interpretation of opiate antagonist trials in dementia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1986, 10, 611-626.	4.8	9
128	Highâ€Dose Naloxone in Older Normal Subjects: Implications for Alzheimer's Disease. Journal of the American Geriatrics Society, 1988, 36, 681-686.	2.6	9
129	Circadian variation in the CSF cortisol concentration of the rhesus monkey. Life Sciences, 1980, 26, 1485-1487.	4.3	7
130	CLINICAL AND EXPERIMENTAL STUDIES OF STRESS AND THE ENDOGENOUS OPIOID SYSTEM. Annals of the New York Academy of Sciences, 1982, 398, 424-432.	3.8	6
131	6-Hydroxydopamine pretreatment effects on ?- and ?-adrenergic receptor adaptation to clorgyline. Naunyn-Schmiedeberg's Archives of Pharmacology, 1985, 329, 158-161.	3.0	6
132	How memory fails: A theoretical model. Geriatric Nursing, 1985, 6, 144-148.	1.9	6
133	A magnetoencephalography spatiotemporal analysis of neural activities during feature binding. NeuroReport, 2005, 16, 1747-1752.	1.2	6
134	Physiologic Concepts That May Revise the Interpretation and Implications of HbA1C in Clinical Medicine. Journal of Diabetes Science and Technology, 2015, 9, 696-700.	2.2	6
135	Do Red Blood Cell Indices Explain Racial Differences in the Relationship between Hemoglobin A1c and Blood Glucose?. Journal of Pediatrics, 2016, 176, 7-9.	1.8	6
136	Functional recreation of age-related CD8 T cells in young mice identifies drivers of aging- and human-specific tissue pathology. Mechanisms of Ageing and Development, 2020, 191, 111351.	4.6	6
137	Peptide Challenges in Affective Illness. Journal of Clinical Psychopharmacology, 1981, 1, 214-222.	1.4	5
138	Assessing pharmacologically induced dopamine receptor sensitivity changes with the ungerstedt turning model. Psychopharmacology, 1981, 75, 212-213.	3.1	5
139	Antidepressants in states of cognitive dysfunction. Drug Development Research, 1984, 4, 517-532.	2.9	5
140	NAPLANAL: A Tool for Analyzing NAPL Saturation and Composition. Ground Water, 2003, 41, 298-299.	1.3	5
141	Epidemiology and Clinical Diagnosis. PET Clinics, 2013, 8, 391-405.	3.0	5
142	Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone. Journal of Diabetes and Its Complications, 2021, 35, 107912.	2.3	5
143	Opiate receptor avidity is increased in rhesus monkeys following unilateral optic tract lesion combined with transections of corpus callosum and hippocampal and anterior commissures. Brain Research, 2000, 879, 1-6.	2.2	4
144	Rationale and Design for a GRADE Substudy of Continuous Glucose Monitoring. Diabetes Technology and Therapeutics, 2019, 21, 682-690.	4.4	4

#	Article	IF	CITATIONS
145	Discordant HbA1c Results: The Hoofbeats Increase. Journal of Pediatrics, 2008, 153, 7-9.	1.8	3
146	The cross-sectional association of cognition with diabetic peripheral and autonomic neuropathy—The GRADE study. Journal of Diabetes and Its Complications, 2021, 35, 108047.	2.3	3
147	The Role of the Immune System in Alzheimer's Disease. Focus (American Psychiatric Publishing), 2009, 7, 28-35.	0.8	3
148	The effects of glutaraldehyde cross-linking on the function of the adenylate cyclase complex of turkey erythrocytes. Life Sciences, 1986, 38, 2151-2161.	4.3	2
149	Can Red Blood Cell Indices Act as Surrogate Markers for Discordance between Hemoglobin A1c and Fasting Blood Glucose?. Clinical Chemistry, 2016, 62, 1551-1553.	3.2	2
150	Failure of High Dose Naloxone to Relieve Tardive Dyskinesia. Journal of Clinical Psychopharmacology, 1987, 7, 364.	1.4	1
151	Longitudinal Measurement of Ventricular Volume Gain in the Healthy Old. Brain Imaging and Behavior, 2009, 3, 370-378.	2.1	1
152	Measurement Of Erythrocyte Survival In Vivo using a Stable Isotope Label In Sickle Cell Anemia. Blood, 2013, 122, 2223-2223.	1.4	1
153	The dynamics of neurotransmitter regulation and antidepressant efficacy. Behavioral and Brain Sciences, 1983, 6, 551.	0.7	0
154	Confidence Limits for Correlations. Journal of Cerebral Blood Flow and Metabolism, 1987, 7, 820-820.	4.3	0